Immunotherapy Drugs Market To Reach $577.2 Billion By 2030

Immunotherapy Drugs Market Growth & Trends

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

 Request a free sample copy or view report summary: Immunotherapy Drugs Market Report

Immunotherapy Drugs Market Report Highlights

• The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.

• The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases

• The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries

• The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
  This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Immunotherapy Drugs Market Segmentation

Grand View Research has segmented the global immunotherapy drugs market based on drug type and region:

Immunotherapy Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies

• Immunomodulator

• Vaccine

Immunotherapy Drugs Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Autoimmune Diseases

• Infectious Diseases

• Others

Immunotherapy Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Immunotherapy Drugs Market

• Amgen Inc.

• Novartis AG

• AbbVie Inc.

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson Services, Inc.

• AstraZeneca

• GSK plc.

• Sanofi

• Bayer AG